By Dr. Asnat Raziel, bariatric surgeon specializing in obesity treatment, metabolic health and healthy longevity; Director of the Multidisciplinary Center for Obesity Treatment, Assia Medical, Assuta Ramat HaChayal, Tel Aviv
Weight loss drugs and pancreatitis: where the concern came from
Weight loss drugs and pancreatitis is a pairing that worries many patients. In recent years, drugs in the GLP-1 family, including semaglutide and tirzepatide, have revolutionized the treatment of obesity and type 2 diabetes. They help people lose a significant amount of weight, improve blood sugar control and reduce cardiac events. However, from early on, reports surfaced of a possible link to acute pancreatitis.
Acute pancreatitis is a medical emergency. It causes severe abdominal pain and, in serious cases, can lead to complications and even death. The concern grew out of cases that doctors reported with the older drugs, such as exenatide and liraglutide. In addition, there were plausible biological explanations for it.
The mechanism: the pancreas, the gallbladder and rapid weight loss
GLP-1 acts on the pancreas: it increases insulin release and reduces glucagon release. However, it also affects the part of the pancreas that makes digestive enzymes. On top of that, these drugs slow the emptying of the gallbladder. Rapid weight loss further raises the risk of gallstones and gallbladder sludge. Such a stone can block the bile ducts and trigger pancreatitis. I explore this link in more depth in my article on gallstones with Wegovy and Mounjaro.
Weight loss drugs and pancreatitis in controlled trials
Most analyses of randomized controlled trials on this question are reassuring. A 2024 meta-analysis included 21 trials of semaglutide versus placebo, with 34,721 participants. The researchers found no increase in the risk of pancreatitis (OR 0.7, 95% confidence interval: 0.5 to 1.2). The result was similar for the pill, for low injectable doses and for high injectable doses.
For tirzepatide, too, the data are reassuring. A 2026 meta-analysis included 19 trials with 15,471 participants. Acute pancreatitis occurred in only 0.22% of participants. Moreover, the risk did not rise as the dose increased from 5 to 15 mg.
Still, the picture is not entirely clear-cut. A large 2025 meta-analysis included 62 trials and 66,232 patients. It found a slight increase in risk (RR 1.44, 95% confidence interval: 1.09 to 1.89). Yet when the researchers grouped the trials by background medications, the difference was no longer significant. As for pancreatic cancer, a 2025 meta-analysis of 48 trials found no increase in risk (OR 0.84).
Weight loss drugs and pancreatitis: the current picture
Taken together, the data point to a fairly clear conclusion. Pancreatitis with GLP-1 drugs is a rare event. If the risk rises at all, the increase is very small. Part of it probably stems from risk factors that are common in this population: obesity, long-standing diabetes, high triglycerides and gallstones. In other words, some of the risk is indirect, through the gallbladder, rather than direct damage from the drug to the pancreas.
We should also keep one limitation in mind: most trials did not include people with a history of pancreatitis. As a result, controlled trials offer less information about this group.
Regulators strengthen the warning
In January 2026, the UK medicines regulator (MHRA) strengthened the warning in the labels of all GLP-1 drugs and tirzepatide. The UK received 1,296 reports of pancreatitis between 2007 and October 2025. Of these, 19 cases ended in death and 24 involved necrotizing pancreatitis. For comparison, pharmacies dispensed about 25.4 million packs of these drugs over the past five years.
The regulator stresses that this side effect is still uncommon, but it can be serious. So it, too, does not state that the link between weight loss drugs and pancreatitis is proven; instead, it calls for vigilance. It advises doctors to ask every patient with abdominal pain whether they take such a drug, because private prescriptions do not always appear in the medical record. Likewise, if a doctor diagnoses pancreatitis, the patient should not restart treatment. Keep this in mind: spontaneous reports signal a need for vigilance, but they do not prove that the drug is the cause.
What about people who have already had pancreatitis?
This is the main knowledge gap. Most of the information comes from retrospective studies, that is, analyses of existing data. A 2024 study examined 258,238 people with diabetes or obesity and a history of pancreatitis. Among those without other risk factors, pancreatitis recurred in 13.8% of GLP-1 users, compared with 40.9% of non-users. With tirzepatide, the recurrence rate was 6.2%, and with semaglutide, 11.7%.
In addition, a 2025 study examined 672,069 patients with diabetes and a history of pancreatitis. Here too, GLP-1 users had fewer recurrences than patients on other diabetes drugs. Nevertheless, the researchers themselves emphasize that we need controlled trials to confirm these findings.
Practical advice on weight loss drugs and pancreatitis
For most patients, the benefits of these drugs far outweigh the rare risk. They lead to significant weight loss, improve blood sugar control and protect the heart and kidneys. You can find general information on this in my article is obesity medication safe? That said, some situations call for extra caution:
- A history of pancreatitis: we weigh each case on its own merits. If the cause has been fixed, for example gallstones removed surgically, treatment with close follow-up may be an option. By contrast, after attacks with no clear cause, many doctors will prefer an alternative.
- Risk factors: known gallstones, triglycerides above 1,000 mg/dL or heavy alcohol use call for an assessment before treatment. It is wise to bring blood lipid levels under control first and to cut back on alcohol.
- Rate of weight loss: losing more than 1.5 kg a week over a long period increases the risk of gallstones. In that case, your doctor can slow the dose escalation, and you should eat regular meals.
Warning signs you should never ignore
Severe, persistent abdominal pain that radiates to the back and comes with nausea or vomiting requires immediate medical attention. In that case, stop the drug until your doctor finds the cause. Similarly, pain in the upper right abdomen, fever, or yellowing of the skin and eyes may point to a gallbladder problem. Also, tell every doctor you see that you take one of these drugs. For guidance on managing the more common side effects, see my article on the side effects of GLP-1 medications.
According to the prescribing information, a history of pancreatitis is not an absolute contraindication. On the other hand, medullary thyroid cancer in the patient or in the family is a contraindication.
The bottom line
Researchers have studied the link between weight loss drugs and pancreatitis in depth in recent years. Most studies found no significant increase in risk, and if a risk exists, it is very small and partly indirect, through gallstones. Meanwhile, reports of severe cases have led regulators to strengthen their warnings. The right approach is therefore a balanced one: offer these drugs to people who will benefit, identify risk factors in advance and know the warning signs. Ultimately, for most patients, the chance of gaining weight loss and metabolic balance far outweighs the rare risk.
This article provides general information and does not replace personal medical advice.
References
Acute pancreatitis due to different semaglutide regimens: An updated meta-analysis
